Background {#Sec1}
==========

Adiponectin is an insulin-sensitising hormone found in multimeric forms in the circulation with the high molecular weight (HMW) 16-18mer (\>400 kDa) being the predominant and active form \[[@CR1]\].

Although an adipokine, unlike other hormones secreted by adipocytes, adiponectin levels are reduced in people with increased central body fat \[[@CR1]\], insulin resistance, type 2 diabetes mellitus and atherosclerosis, as well as in individuals with lipoatrophy and lipohypertrophy \[[@CR1]\]. HMW adiponectin has been shown to correlate better with insulin sensitivity than total adiponectin (TA) \[[@CR2]\] and the HMW:TA ratio to be a better predictor of coronary artery disease than TA \[[@CR3]\]. The ratio has also been shown to be suppressed in type 2 diabetes mellitus patients with coronary artery disease even when HMW and TA levels were unchanged \[[@CR4]\].

In HIV-associated lipodystrophy, a syndrome consisting of fat redistribution, dyslipidaemia and insulin resistance, adiponectin levels are significantly lower, demonstrating a negative correlation with abdominal visceral fat mass and insulin resistance \[[@CR5], [@CR6]\]. This syndrome is associated with antiretroviral (ARV) therapy, particularly protease inhibitors (PIs) (but also nucleotide- and nucleoside reverse transcriptase inhibitors such as stavudine (d4T), zidovudine (AZT)) and didanosine (ddI) \[[@CR7], [@CR8]\]. In such patients, thiazolidinedione administration, via peroxisome proliferator-activated receptor γ activation, leads to improved insulin sensitivity \[[@CR9]\] with upregulation of adiponectin levels, specifically the HMW form \[[@CR10], [@CR11]\]. Adiponectin administration in mice markedly ameliorates protease-induced dyslipidaemia, suggesting that hypoadiponectinaemia may be partially responsible for the metabolic derangements associated with PIs \[[@CR12]\].

In South Africa, the National Department of Health had two highly active antiretroviral therapy (HAART) regimens at the time of this study. The first regimen consisted of d4T, lamivudine (3TC) and either efavirenz (EFV) or nevirapine i.e. a combination of two nucleotide reverse transcriptase inhibitors (NRTIs) and one non-nucleotide reverse transcriptase inhibitor (NNRTIs); while the second regimen consisted of AZT and lopinavir/ritonavir (LPV/r). AZT and ddI are nucleotide- and nucleoside reverse transcriptase inhibitors, respectively, while LPV/r is a PI.

The purpose of this study was to establish whether PI therapy was associated with lower HMW:TA ratios in HIV-infected patients, and to examine associated biochemical evidence of insulin resistance in these patients.

Methods {#Sec2}
=======

This cross-sectional study was performed in accordance with the Helsinki Declaration. The protocol was approved by the University of Cape Town Faculty of Health Sciences Research Ethics Committee with reference number REC 450/2006. Sixty-six HIV-infected African females were enrolled into the study into three groups, viz. PI (Regimen 2 for at least six months), non-PI (Regimen 1 for at least six months) and treatment naïve (TN) groups, each consisting of 22 patients. Subjects were recruited from the ARV clinic at Groote Schuur Hospital, with the non-PI and TN groups matched to the PI group for body mass index (BMI) and age. Exclusion criteria included a history of impaired glucose tolerance or diabetes mellitus, active acute opportunistic infections, renal failure and pregnancy. Written informed consent was obtained. Waist and hip circumferences, weight and height were measured, and the BMI and waist: hip ratio (WHR) calculated. A 75 g OGTT was performed and blood samples drawn at 0 and 120 min. Glucose was measured at both time points and insulin and multimeric adiponectin in the 0 min sample only. Samples were centrifuged and stored at -70°C until analysis. The homeostatic model assessment for insulin resistance (HOMA-IR) and quantitative insulin-sensitivity check index (QUICKI) were calculated. Adiponectin was analysed using the Alpco™ Adiponectin (Multimeric) enzyme immunoassay (sensitivity 0.04 ng/mL and coefficient of variation (CV) \<15%), insulin by the Bayer ACS180 auto-analyser (CV 12%), and glucose by the Bayer Alera chemistry analyser.

Statistical analysis {#Sec3}
--------------------

Results were analysed non-parametrically, using the Mann--Whitney U, Kruskall-Wallis and Spearman correlation tests. Multivariate analyses and power calculations were performed. A p-value of 0.05 was considered significant.

Results {#Sec4}
=======

Patient characteristics {#Sec5}
-----------------------

In the PI group, 21 patients received LPV/r and one Atazanavir for at least six months, with the median duration on PIs being 11.5 months. The median duration on regimen 1 drugs prior to progression to regimen 2 was 15 months. Four (18%) patients received d4T and 13 (59%) AZT, as part of their regimen. The median total duration on these drugs were 15.5 and nine months, respectively. In the non-PI group, 21 of the 22 patients received either AZT or d4T, with median durations of 12 and 10 months, respectively.

The median (interquartile range (IQR) ) age and BMI among the groups were 36 (29; 42) years and 27 (24; 30), respectively. Waist measurement and WHR did not differ among the groups (Table  [1](#Tab1){ref-type="table"}).Table 1**Adiponectin and markers of insulin resistance among the treatment groups (A), duration of therapy among the groups (B)***(A) Adiponectin and markers of insulin resistance among the treatment groups*PI *Median (IQR)*Non-PI *Median (IQR)*TN *Median (IQR)*Unitsp-valueAge34.5 (29.8; 41.0)34.5 (31.3; 41.0)35.5 (29.0; 41.0)Years0.986BMI27.7 (24.9; 30.4)25.0 (23.8; 29.5)25.7 (22.9; 29.7)-0.586Waist89 (82; 95)83 (80; 93)82 (76; 88)cm0.194WHR0.87 (0.82; 0.93)0.85 (0.79; 0.89)0.84 (0.80; 0.90)-0.315Fasting insulin5.5 (2.7; 10.1)3.1 (2.1; 5.7)4.4 (2.0; 8.0)mIU/L0.365Fasting glucose86 (81; 90)91 (83; 98)91 (85; 97)mg/dL0.1452 hour glucose104 (80; 113)94 (85; 109)94 (81; 109)mg/dL0.877HOMA-IR1.18 (0.54; 2.09)0.72 (0.50; 1.17)1.05 (0.41; 1.73)-0.479QUICKI0.37 (0.34; 0.42)0.41 (0.37; 0.43)0.38 (0.35; 0.45)-0.234Total adiponectin5.6 (3.4; 9.4)7.3 (4.0; 8.7)9.0 (7.6; 12.1)ng/mL0.039\*HMW adiponectin2.2 (1.0; 3.9)3.5 (1.8; 5.1)5.3 (3.8; 7.0)ng/mL0.002\*HMW:Total adiponectin0.35 (0.29; 0.42)0.48 (0.41; 0.56)0.56 (0.52; 0.61)-\<0.0001\*\***(B) Duration of therapy among the treatment groups**Regimen 115 (8.5; 21.5)12 (9.5; 20.0)-MonthsRegimen 211.5 (9.3; 14.0)\--Monthsd4T15.5 (9.8; 22.3)10 (8; 17.5)-MonthsAZT9 (5; 16.5)12 (11; 15.0)-MonthsThe Kruskall-Wallis and Mann--Whitney U tests were used to assess differences among the groups collectively and individually, respectively.PI, protease inhibitor group; Non-PI, non-protease inhibitor group; TN, treatment-negative group; IQR, interquartile range; HMW, high molecular weight. \*p \< 0.05; \*\*p \< 0.001. Multiply by the following conversion factor for SI units: glucose 0.0555 (mmol/L); insulin 6.945 (pmol/L).

Adiponectin levels in serum (Figure [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}) {#Sec6}
------------------------------------------------------------------------------------------------------

TA levels were within the reference interval (3.5 -- 22 mg/L) \[[@CR13]\] in all groups. However, total and HMW adiponectin levels were significantly lower in both treatment groups compared to the naïve group, with no significant difference between the PI and non-PI groups. In contrast, the HMW:TA ratio differed among all three groups and was significantly lower in the PI group than in both the non-PI and TN groups, and lower in the non-PI group than in the TN group. This difference was maintained when adjusting for BMI (data not shown) (Table  [1](#Tab1){ref-type="table"} and Figure  [1](#Fig1){ref-type="fig"}).Figure 1**Distribution of (a) Total adiponectin, (b) HMW adiponectin, and (c) HMW: total adiponectin ratio among the three groups.** HMW, high molecular weight; PI, protease inhibitor group; Non-PI, non-protease inhibitor group; TN, treatment-negative group; KW, Kruskall-Wallis; p \<0.05 considered significant.

Traditional markers of insulin resistance {#Sec7}
-----------------------------------------

There were no significant differences among the groups for insulin, fasting and 2-h glucose, and the derived parameters HOMA-IR and QUICKI (Table  [1](#Tab1){ref-type="table"}). However, 15 (23%) of the entire study sample of HIV-infected patients had insulin resistance, defined as HOMA-IR \>1.95 \[[@CR14]\], and their HMW:TA ratios were lower (p = 0.0059) (median 0.31, IQR 0.22 and 0.47) compared to those without insulin resistance (median 0.50, IQR 0.40 and 0.57). Similarly, 40 (60%) of the entire sample of HIV-infected patients were overweight (BMI ≥25) and had significantly lower (p = 0.0475) HMW:TA ratios (median 0.44, IQR 0.31 and 0.54) than those who were not overweight (median 0.50, IQR 0.44 and 0.58).

HMW, TA, and their ratio correlated negatively (p \<0.05) with waist, BMI, fasting insulin and HOMA-IR, even when adjusted for BMI (Table  [2](#Tab2){ref-type="table"}). While HMW, TA, and their ratio correlated positively (p \< 0.05) with QUICKI, this significance was lost when adjusting for BMI. When adjusting for both BMI and total duration of therapy, only the HMW:TA ratio maintained a significant correlation with fasted insulin, HOMA-IR and QUICKI, while all three adiponectin parameters remained significantly associated with waist. TA, HMW and their ratio maintained their association with waist, fasting insulin and HOMA-IR when adjusting for duration of therapy alone. HMW and HMW:TA also remained significantly associated with QUICKI when adjusting for duration of therapy alone.Table 2**The relationship between adiponectin and various markers of insulin resistance before and after adjusting for BMI and duration of therapy, separately and together***Relationship between adiponectin and markers of insulin resistance*UnivariableMultivariable*Adjusted for BMIAdjusted for duration of therapyAdjusted for BMI and duration of therapy*b95% CIp-valueb95% CIp-valueb95% CIp-valueb95% CIp-value**Total Adiponectin**Waist-0.27(-0.3895,-0.1420)0.0001\*\*-0.28(-0.5153,-0.0517)0.019\*-0.29(-0.4582,-0.1161)0.002\*-0.35(-0.6479,-0.0492)0.028\*Fasted Insulin-0.28(-0.4683,-0.0906)0.005\*-0.21(-0.3945,-0.0164)0.037\*-0.28(-0.5408,-0.0266)0.036\*-0.24(-0.4935,0.0099)0.067HOMA-IR-1.11(-1.8677,-0.3428)0.006\*-0.81(-1.5741,-0.0551)0.040\*-1.21(-2.3196,-0.1036)0.038\*-1.07(-2.1435,0.0051)0.058QUICKI14.20(1.2607,27.1444)0.035\*8.24(-4.8207,21.3036)0.22115.25(-0.2780,30.7806)0.06111.29(-4.4271,26.9992)0.167**HMW Adiponectin**Waist-0.17(-0.2484,-0.0923)0.0001\*\*-0.19(-0.3350,-0.0429)0.014\*-0.16(-0.2637,-0.0627)0.003\*-0.19(-0.3674,-0.0109)0.044\*Fasted Insulin-0.17(-0.2941,-0.0547)0.006\*-0.13(-0.2475,-0.0078)0.041\*-0.17(-0.3204,-0.0169)0.035\*-0.14(-0.2918,0.0048)0.065HOMA-IR-0.69(-1.1753,-0.2091)0.007\*-0.51(-0.9903,-0.0273)0.042\*-0.72(-1.3745,-0.0666)0.037\*-0.64(-1.2681,-0.0022)0.056QUICKI9.38(1.2388,17.5231)0.027\*5.67(-2.5563,13.9009)0.1829.97(0.9112,19.0352)0.037\*7.66(-1.5098,16.8289)0.110**HMW: TA**Waist-0.007(-0.0102,-0.0042)0.000\*\*-0.011(-0.0165,-0.0054)0.0003\*\*-0.16(-0.2637,-0.0627)0.003\*-0.007(-0.0130,-0.0016)0.016\*Fasted Insulin-0.008(-0.0123,-0.0030)0.002\*-0.006(-0.0109,-0.0014)0.013\*-0.007(-0.0119,-0.0025)0.005\*-0.006(-0.0111,-0.0018)0.009\*HOMA-IR-0.03(-0.0497,-0.0123)0.002\*-0.03(-0.0442,-0.0063)0.011\*-0.03(-0.0509,-0.0103)0.005\*-0.03(-0.0479,-0.0084)0.008\*QUICKI0.42(0.1036,0.7331)0.011\*0.30(-0.0230,0.6253)0.0730.44(0.1586,0.7148)0.004\*0.38(0.0911,0.6598)0.014\*HMW, high molecular weight; b, coefficient; CI, confidence interval. \*p \< 0.05; \*\*p \< 0.001.

Discussion {#Sec8}
==========

Altered body composition and insulin resistance are components of the HIV--associated lipodystrophy syndrome \[[@CR7]\]. This syndrome is primarily seen in HIV-infected patients on HAART, with a 17% risk of developing lipodystrophy after the first year of HAART and each additional 6 month period associated with a 45% risk \[[@CR15]\]. These findings are particularly associated with PIs, but similar findings have been seen in some patients on nucleotide and nucleoside analogues such as d4T, AZT and ddI \[[@CR8]\].

Adiponectin has been implicated in the pathogenesis of HIV-- associated lipodystrophy \[[@CR12]\], with PI administration in mice producing a dose-related reduction in adiponectin levels and administration of recombinant adiponectin ameliorating the associated dyslipidaemia.

It was therefore somewhat surprising that TA levels were well within the reference interval in all our study groups. However, they were significantly lower in the HIV-infected patients on HAART therapy (both PIs and non-PIs) than in those not receiving treatment.

The active HMW form of adiponectin has been shown to correlate better with insulin sensitivity than TA \[[@CR16]\], and has been shown to be low in HIV-infected patients with insulin resistance \[[@CR10]\]. In our study, HMW adiponectin levels were significantly lower in patients receiving both PIs and non-PIs, but also in those receiving only non-PIs. This finding in the latter group, may be attributed to the use of d4T (16 (66%) patients) or AZT (5 (23%) patients), drugs which have both been associated with lipodystrophy \[[@CR17]\].

The HMW:TA ratio is a superior marker of insulin resistance compared to total and HMW adiponectin levels individually \[[@CR18]\]. It is also an independent risk factor for coronary vascular disease (CVD) \[[@CR19]\]. Previous studies have shown increased cardiovascular risk in HIV-infected patients, including those on HAART \[[@CR20], [@CR21]\]. We found this ratio to be significantly lower in the PI and less so (but nevertheless still significantly so) in the non-PI groups. This may imply an increased risk for CVD in patients on HAART (consistent with the findings of others) \[[@CR20], [@CR21]\], with the risk for CVD increased when both PIs and non-PIs are being used. This significantly lower HMW:TA ratio in patients receiving both PIs and NRTIs (with the majority, i.e. 17 of 22, of patients also receiving a thymidine analogue) confirms previous findings that protease inhibitors and thymidine analogues induce metabolic complications synergistically \[[@CR7]\]. A limitation in this study is that the PI group also contained the nucleoside analogue ddI. Further studies are needed in the absence of so called d-drugs to confirm the contribution of PI drugs to the changes seen in this study.

Our patient groups were selected to exclude the presence of overt diabetes, and therefore it was not surprising that fasting glucose was not abnormal in any of the groups. On the other hand, we were surprised by the lack of difference in all measures of glucose tolerance and insulin sensitivity among the groups (Table  [1](#Tab1){ref-type="table"}), despite the difference seen among the groups in total and HMW adiponectin. However, a larger study sample may be required to verify this. The sample size was sufficiently powered (75.5%) to detect a difference in HMW: TA, but not to verify the lack of significant differences demonstrated for the insulin resistance markers. A further limitation is that visceral and subcutaneous adiposity were not quantitatively assessed. Notwithstanding, the relationship between insulin resistance markers and adiponectin, previously shown \[[@CR5]\], was demonstrated here, with the HMW:TA ratio shown to be significantly lower in patients (in all groups) with established insulin resistance (HOMA-IR greater than 1.95 \[[@CR21]\]) and also significantly lower in patients with BMI greater than or equal to 25 than in those with lower BMIs. Furthermore, adiponectin levels (high, total and their ratio) correlated negatively with HOMA-IR and positively with QUICKI. The HMW:TA ratio also correlated negatively with waist, waist hip ratio (data not shown), fasting insulin levels and BMI (data not shown) - all markers of insulin resistance. While BMI and duration of drug therapy collectively contribute to the association seen between the markers of insulin resistance and the TA and HMW adiponectin forms, they do not affect the associations seen with the HMW:TA ratio.

Conclusion {#Sec9}
==========

These data demonstrate that both PI- and non-PI-containing HAART regimens significantly lower the HMW:TA ratio in HIV patients, with the ratio more significantly decreased in the PI-containing regimen, implying that PIs and NRTIs have an additive effect on the HMW:TA ratio. Although the HMW:TA ratio correlated negatively with indirect markers of insulin resistance, insulin resistance was not demonstrated to be associated with ARV drugs. We therefore propose that the HMW:TA ratio may be an earlier or more sensitive marker of insulin resistance in HIV-infected patients on HAART than conventional markers or HMW and total adiponectin individually.
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